Clinical Trial Update: Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating MK-4166 alone and with pembrolizumab (MK-3475) in advanced solid tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• MK-3475 (pembrolizumab)
• MK-4166 (MK-4166)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2020-07-31